Estamos no ar no ! Saiba mais

Definium Therapeutics

DFTX

Valor de mercado US$ 4,31 bi

32,10 USD

-2,16

6,3%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

32,02

-0,08

0,25%

1 dia

-6,3%

5 dias

-11,5%

1 mês

-15,19%

3 meses

-27,21%

6 meses

42,92%

No acumulado do ano

135,34%

1 ano

169,52%

5 anos

-6,55%

10 anos

-46,77%

Sobre: Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Funcionários: 106

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 32,3%

Neutro 67,7%

Negativo 0%

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 2026.

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September.

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics NASDAQ: DFTX Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open-label portions of the studies still underway.

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivotal-study results previously reported in GAD and major depressive disorder.

Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study

Zacks Investment Research

Definium Reports Second Phase III Success in Anxiety Disorder Program

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

Definium Reports Second Phase III Success in Anxiety Disorder Program

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.

Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.

First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.

Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

Definium Therapeutics Inc. (NASDAQ:DFTX) on Monday released topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).

Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

Investors Business Daily

Definium, Up 190% This Year, Succeeds Again With Synthetic LSD; Shares Fly

Definium Therapeutics' synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again.

Definium, Up 190% This Year, Succeeds Again With Synthetic LSD; Shares Fly

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company's second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company's third.

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™